In an exciting announcement from the United Kingdom’s National Health Service (NHS), patients with Sickle Cell Disease can now be prescribed Voxelotor, a Pfizer-developed drug that can significantly improve quality of life for those aged 12 and over. The new drug requires fewer required hospital visits and offers a better overall health outcome for many, in addition to reducing the daily impact of SCD. With the potential of Voxelotor to make an immense impact on SCD treatments, the NHS’ approval has been welcomed by many health organizations, including the Caribbean and African Health Network (CAHN) and the Sickle Cell Society – with more than 4,000 patients now eligible for treatment.

At OxyDial, our primary mission is to advance and improve treatments for SCD, and we’re absolutely thrilled to see the addition of Voxelotor to the NHS’ treatment options for sickle cell patients. We believe in the power of leveraging advanced solutions to enhance the quality of life for those suffering from life-threatening blood disorders, and are eager to continue pushing the envelope of what we can do to make that a reality for those across the globe.

Read more:

#NHS #SickleCell #Pfizer #Voxelotor #SCDTreatment